Novocure

New Capabilities

As of June 2026: Publicly traded; Optune Pax launched in U.S. with 83 patients on therapy after seven weeks; Germany and Japan launches planned for H2 2026; pursuing metastatic indication via PANOVA-4

Pancreatic cancer kills roughly 52,000 Americans each year and carries a five-year survival rate of 13 percent. In February 2026, the FDA approved Optune Pax, the first new treatment for locally advanced disease in nearly 30 years, adding alternating electric fields to the treatment options alongside chemotherapy.

Updated Jun 3